GSK seeks EU approval for 2-dose cervical cancer vaccine

08/9/2013 | Pharmaceutical Business Review Online

GlaxoSmithKline filed an application with the European Medicines Agency seeking approval to administer its cervical cancer vaccine Cervarix in a two-dose schedule in girls 9 to 14. The drug is intended to protect girls from premalignant genital lesions and cervical cancer caused by certain HPV types.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC